drugset / Trial / NCT01384747
Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
Phase 4
Terminated
186 enrolled
CardioVascular Research Foundation
Boryung Pharmaceutical Co., Ltd · collabCardioVascular Research Foundation, Korea · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
* Fimasartan will be more beneficial in stabilizing the plaque vulnerability compared to control group in deferred coronary lesions. * Fimasartan will be more beneficial in reducing total plaque volume compared to control group in deferred coronary lesions. * Fimasartan will be more beneficial in reducing functional impairment of stenotic lesions (assessed by FFR:Fractional Flow Reserve) in deferred coronary lesions.
Timeline
- Start
- 2011-07
- Primary completion
- 2018-03
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fimasartan | Small molecule | 120 mg | — |